HomeCompareFLSS vs ABBV

FLSS vs ABBV: Dividend Comparison 2026

FLSS yields 20000000.00% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FLSS wins by $1.378983907781291e+33M in total portfolio value
10 years
FLSS
FLSS
● Live price
20000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.378983907781291e+33M
Annual income
$1,365,233,528,321,427,000,000,000,000,000,000,000,000.00
Full FLSS calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — FLSS vs ABBV

📍 FLSS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFLSSABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FLSS + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FLSS pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FLSS
Annual income on $10K today (after 15% tax)
$1,700,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$1,160,448,499,073,213,000,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, FLSS beats the other by $1,160,448,499,073,213,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FLSS + ABBV for your $10,000?

FLSS: 50%ABBV: 50%
100% ABBV50/50100% FLSS
Portfolio after 10yr
$6.894919538906455e+32M
Annual income
$682,616,764,160,713,500,000,000,000,000,000,000,000.00/yr
Blended yield
99.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

FLSS
No analyst data
Altman Z
-3.6
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FLSS buys
0
ABBV buys
0
No recent congressional trades found for FLSS or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFLSSABBV
Forward yield20000000.00%3.12%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$1.378983907781291e+33M$104.7K
Annual income after 10y$1,365,233,528,321,427,000,000,000,000,000,000,000,000.00$25,725.73
Total dividends collected$1.3780804039422322e+33M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FLSS vs ABBV ($10,000, DRIP)

YearFLSS PortfolioFLSS Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$1,000,010,700$1,000,000,000.00$11,559$438.51+$1000.00MFLSS
2$46,730,541,974,066$46,729,471,962,616.81$13,494$640.86+$46730541.96MFLSS
3$1,020,456,630,513,561,600$1,020,406,628,833,649,400.00$15,951$945.97+$1020456630513.55MFLSS
4$10,413,549,150,437,309,000,000$10,412,457,261,842,660,000,000.00$19,152$1,413.89+$10413549150437308.00MFLSS
5$49,663,934,918,154,680,000,000,000$49,652,792,420,563,720,000,000,000.00$23,443$2,146.38+$49663934918154682368.00MFLSS
6$110,708,450,458,551,960,000,000,000,000$110,655,310,048,189,540,000,000,000,000.00$29,391$3,321.96+$1.1070845045855196e+23MFLSS
7$115,383,637,844,852,680,000,000,000,000,000$115,265,179,802,862,020,000,000,000,000,000.00$37,948$5,265.87+$1.1538363784485268e+26MFLSS
8$56,260,281,340,608,930,000,000,000,000,000,000$56,136,820,848,114,940,000,000,000,000,000,000.00$50,795$8,596.74+$5.626028134060893e+28MFLSS
9$12,850,821,925,106,690,000,000,000,000,000,000,000$12,790,623,424,072,240,000,000,000,000,000,000,000.00$71,034$14,549.41+$1.285082192510669e+31MFLSS
10$1,378,983,907,781,291,200,000,000,000,000,000,000,000$1,365,233,528,321,427,000,000,000,000,000,000,000,000.00$104,715$25,725.73+$1.378983907781291e+33MFLSS

FLSS vs ABBV: Complete Analysis 2026

FLSSStock

Forbes Energy Services, Ltd., an independent oilfield services contractor, provides a range of well site services for oil and natural gas drilling and producing companies to develop and enhance the production of oil and natural gas in the United States. It operates through three segments: Well Servicing, Coiled Tubing, and Fluid Logistics. The Well Servicing segment offers well maintenance services, including remedial repairs, and removal and replacement of downhole production equipment; well workovers, such as downhole repairs, re-completions, and re-perforations; completion and swabbing services; plugging and abandonment services; and pressure testing services of oil and natural gas production and scanning tubing for pitting and wall thickness. The Coiled Tubing segment provides various services, such as horizontal completions, well bore clean-outs and maintenance, nitrogen, thru-tubing, formation stimulation using acid and other chemicals, and other pre-and post-hydraulic fracturing well preparation services. The Fluid Logistics segment transports, stores, and disposes various drilling and produced fluids used in oil and natural gas production. This segment is involved in fluid hauling activities; the disposal of salt water, and incidental non-hazardous oil and natural gas wastes produced from oil and natural gas wells; rental of fluid storage tanks for use by oilfield operators to store various fluids at well sites; and sale and transportation of various chemicals and fluids used in drilling, completion, and workover operations for oil and natural gas wells. As of December 31, 2019, the company operated a fleet of 141 well servicing rigs comprising 134 workover rigs and 7 swabbing rigs; 103 fluid service vacuum trucks, trailers, and other hauling trucks; 11 disposal wells; 2,534 fluid storage tanks; and 14 coiled tubing units. Forbes Energy Services, Ltd. was founded in 2003 and is headquartered in Alice, Texas.

Full FLSS Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this FLSS vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FLSS vs SCHDFLSS vs JEPIFLSS vs OFLSS vs KOFLSS vs MAINFLSS vs JNJFLSS vs MRKFLSS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.